NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its second quarter revenues were flat year over year, falling short of the consensus Wall Street estimate.

The Redwood City, California-based molecular diagnostics firm had total revenues of $70.6 million for the three months ended June 30, compared to $70.5 million in the second quarter of 2014. It fell short of the consensus Wall Street estimate of $71.7 million.

As in the first quarter, all of Genomic Health's revenues in the most recent quarter came from product sales.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.